← Browse by Condition
Medical Condition

anticoagulant adverse reaction

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 4

ClinicalMetric tracks all active clinical trials for anticoagulant adverse reaction sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — anticoagulant adverse reaction Clinical Trials

How many clinical trials are currently recruiting for anticoagulant adverse reaction?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for anticoagulant adverse reaction, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for anticoagulant adverse reaction?
anticoagulant adverse reaction research spans Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a anticoagulant adverse reaction clinical trial?
Eligibility criteria for anticoagulant adverse reaction trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 4
1
Top Sponsors
University Hospital, Antwerp 1 trial
Helse Nord-Trøndelag HF 1 trial
China National Center for Cardiovascular Diseases 1 trial

Recruiting Clinical Trials

NCT06079021
Recruiting
COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device
Enrollment
20 pts
Location
Belgium
Sponsor
University Hospital, Antwerp
View Trial →
NCT04556188
Recruiting
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
Enrollment
200 pts
Location
Ethiopia, Norway
Sponsor
Helse Nord-Trøndelag HF
View Trial →
NCT06108414 Phase 4
Recruiting
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
Enrollment
4,374 pts
Location
China
Sponsor
China National Center for Card...
View Trial →

Related Conditions

acute on chronic liver failure (1) sarcopenia (1) ultrasonography (1) rheumatic heart disease (1) atrial fibrillation (1) stroke (1) major adverse cardiac events (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology